Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors

Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1300-11.

Abstract

Purpose: To examine the apoptotic effect induced in human retinoblastoma Y79 cells by camptothecin, etoposide, and amsacrine, to examine the effect of these drugs on the expression of many apoptosis-related modulators, and to test the antiapoptotic effect exerted by insulin-like growth factor-I (IGF-I).

Methods: Morphologic features of apoptosis were demonstrated using acridine orange- ethidium bromide staining and electron microscopy. DNA fragmentation was determined by means of an in situ cell detection procedure (TdT-dUTP terminal nick-end labeling [TUNEL]) or by electrophoresis on agarose gels and was quantified by enzyme-linked immunosorbent assay. The expression of apoptosis-related modulators was studied by western blot analysis. The processing of latent p53 was examined by means of pulse- chase analysis.

Results: Camptothecin, etoposide, and amsacrine induced apoptosis in Y79 cells in a dose-dependent manner; camptothecin was the most efficacious compound. The effect, which was dependent on macromolecular synthesis, appeared after a lag of 8 hours and increased for as long as 24 hours. It was lower in cells treated with IGF-I, a potent mitogenic factor. Camptothecin and etoposide increased the p53 level after 4 hours of treatment, before the onset of apoptosis. This effect seemed to be a consequence of the conversion of latent p53 to one that is transcriptionally active. The drugs also induced an increase in p53-related proteins, such as p21, Bax, and IGF binding protein-3 (IGF-BP3), and caused a significant reduction of the Bcl-2 level. The latter effect was less evident in cells pretreated with IGF-I.

Conclusions: Topoisomerase inhibitors induce apoptosis in Y79 cells. This event is accompanied by a decrease in the expression of Bcl-2, a death antagonist, and an increase in that of Bax, a death agonist. A probable consequence of these modifications is the activation of ICE-like activity with degradation of poly-(adenosine diphosphate [ADP] ribose)-polymerase. Insulin-like growth factor-I exerts an antiapoptotic action in Y79 cells, and this function is most likely reduced by the overexpression of IGF-BP3 that is induced by drug treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amsacrine / pharmacology
  • Apoptosis / drug effects*
  • Camptothecin / pharmacology
  • Cell Survival / drug effects
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins / metabolism
  • Cycloheximide / pharmacology
  • DNA Damage / drug effects
  • DNA Topoisomerases, Type I / metabolism
  • DNA, Neoplasm / analysis
  • DNA, Neoplasm / drug effects*
  • Dactinomycin / pharmacology
  • Enzyme Inhibitors / pharmacology*
  • Etoposide / pharmacology
  • Humans
  • Insulin-Like Growth Factor Binding Protein 3 / metabolism
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Retinal Neoplasms / drug therapy
  • Retinal Neoplasms / enzymology
  • Retinal Neoplasms / pathology*
  • Retinoblastoma / drug therapy
  • Retinoblastoma / enzymology
  • Retinoblastoma / pathology*
  • Topoisomerase I Inhibitors*
  • Tumor Cells, Cultured
  • Tumor Suppressor Protein p53 / metabolism
  • bcl-2-Associated X Protein

Substances

  • BAX protein, human
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • DNA, Neoplasm
  • Enzyme Inhibitors
  • Insulin-Like Growth Factor Binding Protein 3
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Topoisomerase I Inhibitors
  • Tumor Suppressor Protein p53
  • bcl-2-Associated X Protein
  • Amsacrine
  • Dactinomycin
  • Etoposide
  • Cycloheximide
  • DNA Topoisomerases, Type I
  • Camptothecin